Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy
Open accessAbstract
Administration of an anti-tau antibody to transgenic mice expressing human tau and to patients with tauopathy increased the concentration of tau in plasma.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In PS19 mice, plasma tau inversely correlated with brain soluble tau, suggesting peripheral tau levels reflect changes occurring in the CNS.
“In PS19 mice, plasma tau was found to inversely correlate with brain soluble tau levels, suggesting that peripheral tau levels reflect changes occurring in the CNS (Yanamandra et al., 2017).”
From Alzheimer Disease: An Update on Pathobiology and Treatment Strategies (2019) · cites this paper as Yanamandra et al., 2017
A fall in the phosphorylation rate of some sites (for example, pT181 and pT217) while aggregated tau rises might reflect sequestration by hyperphosphorylated aggregates.
“these results might suggest that a reduction in the phosphorylation rate of some sites (for example, pT181 and pT217) when aggregated tau is increasing could represent a process of sequestration by hyperphosphorylated aggregates48.”
From A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer’s disease (2020) · cites this paper as [48]
Anti-tau protein monoclonal antibodies are a promising therapeutic strategy, but further exploration of their mechanism of action and side-effects is still needed.
“anti-tau protein monoclonal antibodies are a promising therapeutic strategy, but further exploration of their mechanism of action and side-effects is still needed [194].”
From Role of Tau Protein in Neurodegenerative Diseases and Development of Its Targeted Drugs: A Literature Review (2024) · cites this paper as [194]
Monoclonal antibodies against the amino-terminal or repeat domain (306-320) region, oligomeric tau, misfolded tau, pSer202, pThr231, pSer409, pSer413 and pSer422 have proved to be efficacious in tauopathy models.
“In addition, monoclonal antibodies against the amino-terminal or repeat domain (306–320) region209–215, oligomeric tau216,217, misfolded tau201,218,219, pSer202220,221, pThr231208 pSer409222, pSer413223 and pSer422224 have proved to be efficacious in tauopathy models.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [211]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 51 · Cited by 100
Research works printed but not linked: 1
- [50]Franklin KBJ Paxinos G The mouse brain in stereotaxic coordinates Academic Press San Diego 1997
- Authors
- Yanamandra, K., Patel, T. K., Jiang, H., Schindler, S., Ulrich, J. D., Boxer, A. L., Miller, B. L., Kerwin, D. R., Gallardo, G., Stewart, F., Finn, M. B., Cairns, N. J., Verghese, P. B., Fogelman, I., West, T., Braunstein, J., Robinson, G., Keyser, J., Roh, J., Knapik, S. S., Hu, Y., & Holtzman, D. M.
- Affiliations
- Washington University in St. Louis (US)
- University of California, San Francisco (US)
- Texas Health Dallas (US)
- C2N Diagnostics (United States) (US)
- Corresponding author
- Yanamandra, Kiran
- Patel, Tirth K.
- Holtzman, David M.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-04-19
- Volume
- 9
- Issue
- 386
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5727571
- OpenAlex
- W2605473592
- Cited by
- 100
- References
- 51
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 9 · 2023: 13 · 2022: 8 · 2021: 10 · 2020: 17 · 2019: 15 · 2018: 16 · 2017: 3
- FWCI
- 10.31
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- JPB Foundation
- NIH (R01AG048678)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- tauopathy, anti-tau antibodies, passive immunization, plasma tau, tau transgenic mice, soluble tau, neurodegeneration, 3-nitropropionic acid, neuronal injury, tau aggregation
- MeSH terms
- Animals, Antibodies, Brain, Disease Models, Animal, Dose-Response Relationship, Drug, Humans, Mice, Transgenic, Nitro Compounds, Propionates, tau Proteins, Tauopathies, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
